Table 1.
A summary of the infectivity of SMA-treated PrPSc samples in samples from Hyper-infected hamsters and RML-infected mice
In both Hyper-infected hamsters and RML-infected mice, 10% brain homogenates and Sarkosyl-purified PrPSc were used as controls.
| Sample | Incubation period ± S.E. | N/N0 |
|---|---|---|
| days | ||
| Samples from Hyper-infected hamsters | ||
| 1% 263K brain homogenate (control) | 71 ± 0.5 | 4/4 |
| Treated with 1% sarkosyl-PrPSc (control) | 76 ± 5 | 12/12 |
| Treated with 1% SMA(1:1)ma-PrPSc | 84 ± 8 | 12/12 |
| Treated with 1% SMA(2:1)-PrPSc | 87 ± 3 | 12/12 |
| Treated with 1% SMA-SH-PrPSc | 88 ± 4a | 12/12a |
| Treated with 1% SMA(3:1)-PrPSc | 94 ± 3a | 12/12a |
| Samples from RML-infected mice | ||
| Treated with 1% sarkosyl-PrPSc (control) | 158 ± 19 | 19/19 |
| Treated with 1% SMA(1:1)ma-PrPSc | 174 ± 27 | 9/9 |
| Treated with 1% SMA(2:1)-PrPSc | 172 ± 21 | 15/15 |
| Treated with 1% SMA-SH-PrPSc | 163 ± 15 | 14/14 |
| Treated with 1% SMA(3:1)-PrPSc | 187 ± 33.5a | 17/17a |
a Significant difference (p value < 0.001) between the incubation periods of SMA-treated samples and sarkosyl-purified PrPSc.